- Creso Pharma (CPH) has now sold over 3 million doses of its anibidiol granule sachets since its launch in 2017
- The granules are a form of complementary feed, designed to reduce stress and improve wellbeing in dogs.
- The hemp-derived range was commercialised in partnership with Vibrac and is sold in over 10 European countries
- Sales from the range grew around 700 per cent in 2019
- Creso Pharma says it has another three hemp-derived products slated for launch this year
- Company shares lost 2.63 per cent today to close at 18.5 cents apiece
Creso Pharma (CPH) has now sold over three million Anibidiol granule sachets since the products launch in 2017.
Creso produces cannabis and hemp based products to improve both human and animal health and wellbeing.
The anibidiol granules is designed to reduce stress levels and boost wellbeing in cats and dogs.
The granulated delivery system is patented by Creso and allows the product to be mixed into the animal’s feed.
Anibidiol was commercialised in collaboration with Vibrac, a pharmaceutical laboratory specialised in animal health.
Creso Pharma CEO and co-founder Dr Miri Halperin Wernli said the strong sales are paving the way for expansion into additional markets.
“This achievement is paving the way for launches into additional countries on other continents such as North and Latin America, where we observe a growing need for natural complementary feed to help mitigate stress and improve the wellbeing of pets,” he said.
“Creso Pharma hopes to continue leveraging the rising global trend of the ‘humanisation’ of pets, in which people treat their pets as best friends or family members,” he continued.
Creso Pharma has developed three additional hemp based products slated for launch with Vibrac in 2020.
One of the products is designed for horses and is set to be launched in April. The other two products are for cats and dogs and will be launched in the fourth quarter.
Company shares lost 2.63 per cent today to close at 18.5 cents apiece.